Sunday, April 05, 2026

Novel Acid-Tolerant Bioadhesive for Gastric Perforation

A NOVEL injectable acid-tolerant bioadhesive, composed of FDA-approved components, for sutureless repair of large gastric perforation has been unveiled by scientists. 

The groundbreaking OSSA hydrogel, formed using Octa-PEG-NHand Octa-PEG-SSA, holds significant promise for the clinical treatment of digestive diseases, researchers reported.  

Gastric Perforation at 4 mm 

Adhesion to wet surfaces is paramount for effective wound healing in cases of gastric perforation because of harsh gastric juice, researchers reported. 

The OSSA hydrogel was injected to seal a 4 mm hole on a porcine colon. 

The pressure required to burst the adhesive far exceeded commercially available treatments: Coseal, Fibrin glue, and Histoacryl.  

Further, the OSSA hydrogel did not break with significant motion, only violent puncture and peeling.  

Gastric Perforation at 10 mm 

Researchers then deposited the OSSA hydrogel in situ on the damaged tissues of a larger, approximately 10 mm, incision on a porcine stomach, which was subsequently filled with more than 5 kg of water. 

There was no fluid leakage and the OSSA hydrogel was physically robust, not just adhesive. 

Gastric Perforation at 20 mm 

Next, researchers created an incision of around 20 mm in an isolated porcine stomach.  

Again, they injected the adhesive in situ, pre-stained with blue dye.  

They observed ultrafast gelation, instant adhesion, fluid-tight capacity, and no significant glue leakage. 

The adhesive remained firm for more than 72 hours, even when the porcine stomach was submerged in putrid water, researchers reported.  

In fact, in human gastric juices, the adhesion onto damaged tissues lasted even longer, remaining robust for more than 2 weeks.  

Performance Against Surgical Suture 

Researchers compared OSSA, Coseal, and Histoacryl sealants, alongside surgical suture.  

Firstly, the sealants were easily delivered and robustly adhered within a short amount of time, whereas surgical suture took more than 15 minutes.  

There were no observable leakages of gastric contents after all treatments.  

However, the OSSA bioadhesive achieved a superior repair efficacy compared with the clinical suture.  

On top of this, it exhibited significantly lower levels of abdominal adhesions at repair sites and in surrounding tissues. 

A New Treatment for Gastric Perforation? 

OSSA hydrogel marks a significant potential treatment option in gastrointestinal repair and postoperative adhesion prevention, researchers stressed.   

It enabled strong adhesion in fluidically, chemically, and mechanically dynamic gastric environments.  

Despite being in early developmental stages, the bioadhesive provides a promising clinical therapeutic opportunity for both large gastric perforation and other digestive injuries via minimally invasive techniques, scientists concluded. 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

 

Labels: , , , , , , , ,

Wednesday, June 17, 2020

Novel insulin found as effective as insulin glargine in phase 2 trial


Researchers have announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analog which were presented during the 80th Scientific Sessions of the American Diabetes Association.

In the trial, adults with type 2 diabetes randomized to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared to adults with type 2 diabetes randomized to once-daily insulin glargine U100.

This 26-week, randomized, double-blind, double-dummy, treat-to-target phase 2 clinical trial involved 247 insulin-naïve adults with type 2 diabetes inadequately controlled with metformin with or without a DPP-4i. The primary endpoint showed that the change from baseline to week 26 in blood sugar control (A1C) was similar in participants receiving once-weekly insulin icodec compared to once-daily insulin glargine U100 (-1.33 vs -1.15 percentage points, respectively, 
p=0.08).1 Secondary endpoints included change in fasting plasma glucose (FPG) from baseline to week 26, which was similar for insulin icodec and insulin glargine U100 (-58mg/dL and -54mg/dL respectively), and the change from baseline to week 26 of the mean of the nine-point self-monitoring of blood glucose (SMBG) profile, which was greater for icodec (-7.9 mg/dL; p= 0.01).1

“Many people with type 2 diabetes are reluctant to start on insulin therapy due to the need for daily injections," said Dr. Julio Rosenstock, lead trial investigator and clinical professor of medicine, University of Texas Southwestern Medical Center, US. "I'm truly excited about the potential of such innovative treatments which could reduce the number of basal insulin injections for my patients with diabetes."

Hypoglycemia, also known as a hypo or low blood sugar, was similar for both treatment groups (observed rates of level 2 [<54 100="" 3="" 45.6="" 52.5="" adverse="" an="" and="" arms.1="" between="" dl="" event="" events="" exposure="" for="" glargine="" had="" hypoglycemia="" icodec="" identified="" in="" insulin="" issues="" mg="" nbsp="" new="" no="" of="" once-weekly="" patient="" patients="" per="" proportion="" relation="" respectively="" safety="" severe="" similar="" span="" that="" the="" this="" to="" trial.="" u100="" was="" were="" years="">


"Novo Nordisk continues to be a leader in insulin innovation, advancing research for nearly 100 years in order to help improve the lives of those living with diabetes," said Todd Hobbs, vice president and chief medical officer for Novo Nordisk in the US. "Data from our phase 2 trial of investigational, once-weekly icodec showed that in terms of efficacy and safety, icodec was comparable to insulin glargine U100 and could provide those living with type 2 diabetes a new option allowing for a reduction in the amount of basal insulin injections from seven to once per week."

Novo Nordisk expects to initiate the phase 3 clinical development program for once-weekly insulin icodec later in 2020.

 
This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.     

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement


Labels: , , , , , , ,